McClellan, Wall Street and Increasing FDA Predictability

01 Mar 2003

The most encouraging aspect of the series of speeches the FDA's new commissioner, Mark McClellan, MD, PhD, has been giving is not what he says--we've heard most of this before--but to whom he says it: pharmaceutical investors and companies.

The most encouraging aspect to the series of speeches the FDA's new commissioner, Mark McClellan, MD, PhD, has been giving is not what he says—we've heard most of this before—but whom he says it to: pharmaceutical investors and companies.

In February, McClellan made keynote addresses to two investor meetings in New York City outlining his plans to shorten drug...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Kris Joshi Named Norstella CEO, Prioritizes AI Innovation

09 Jul 2025

• By Aakash Babu

Joshi joins the parent company of Citeline, which houses flagship publications In Vivo, Scrip and Pink Sheet, to focus on AI, business harmonization and long-term growth.

Rising Leaders 2025: Regeneron’s Karen Rodriguez Lorenc On Not Believing In Failure

09 Jul 2025

• By Jo Shorthouse

Karen Rodriguez Lorenc has overseen linvoseltamab's development and subsequent approval in Europe, now waiting for its US fate, she talked to In Vivo about how patient-centric drug development philosophy is core to her leadership, and why she doesn't believe in failure.

Podcast: Acuitas CSO On CRISPR Delivery Breakthrough And Next-Gen Lipid Nanoparticle Technology

08 Jul 2025

• By David Wild

In Vivo sits down with Ying Tam, CSO at Acuitas Therapeutics, to discuss the company's role in delivering the first personalized CRISPR treatment to an infant and the clinical implications of new lipid nanoparticle technologies.

Titans Of Pharma: Lilly’s Ricks Tops Big Pharma Pay Chart

07 Jul 2025

• By Eleanor Malone, Edwin Elmhirst, and Kosh Naran

The big pharma CEO with the highest-valued compensation in 2024 was David Ricks of Eli Lilly, while Pfizer and J&J executives slipped into third and fourth place behind AbbVie's now retired chief Richard Gonzalez. European firms brought up the rear.